| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
Neoandrographolide inhibits osteoclast differentiation and bone resorption through the inhibition of the MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathways. It also has anti-inflammatory effects, partly through inhibition of iNOS and COX-2 expression via p38 MAPK.
|
|---|---|
| ln Vitro |
Neoandrographolide shows anti-inflammatory activity in vitro by inhibiting the expression of iNOS and COX-2. It inhibits osteoclast differentiation and bone resorption. It also inhibits NO production ex vivo (35-40% suppression at 5-25 mg/kg/d oral dosing) and has potent hypolipidemic effects.
|
| ln Vivo |
Neoandrographolide has potent hypolipidemic effects and protects the cardiovascular system without significant liver damage. It inhibits and delays the rise in body temperature caused by pathogens and has cough-relieving and asthma-relieving effects. It shows a positive effect on the prevention and treatment of heat stroke.
|
| Enzyme Assay |
Neoandrographolide is not typically studied in direct enzyme/receptor binding assays, but rather in cell-based functional assays. Its anti-inflammatory activity is assessed by measuring its effect on signaling pathways like MAPK, NF-κB, and PI3K/AKT in cell-free or cell-based systems. The inhibition of these pathways is a key readout.
|
| Cell Assay |
In vitro experiments are performed using various cell types, including osteoclasts, macrophages, and other inflammatory cells. Cells are treated with neoandrographolide, and the expression of inflammatory mediators (iNOS, COX-2) and activation of signaling proteins (p38 MAPK) are measured by Western blot or ELISA.
|
| Animal Protocol |
In vivo studies are conducted in animal models of inflammation, bone loss, and dyslipidemia. For example, its effects on body temperature in response to pyrogens are studied. Its hypolipidemic and cardiovascular protective effects are evaluated in models of metabolic syndrome. It shows oral bioavailability and in vivo efficacy.
|
| ADME/Pharmacokinetics |
Neoandrographolide has a molecular weight of 480.59 g/mol. It is a glucoside, which contributes to its oral bioavailability, a key advantage over its aglycone andrographolide. Its pharmacokinetic properties, including Cmax, have been characterized in studies.
|
| Toxicity/Toxicokinetics |
Toxicological data suggests that neoandrographolide has a favorable safety profile, with no significant liver damage reported. Its safety has been evaluated in preclinical studies. It is a natural product with a long history of use in traditional medicine.
|
| References |
Banerjee T, Singh A, Kumar S, Dhanani T, Gajbhiye NA, Koley TK, Maurya A, Filgona J. Ovicidal and larvicidal effects of extracts from leaves of Andrographis paniculata (Burm. f.) Wall.ex Nees against field isolates of human hookworm (Ancylostoma duodenale). J Ethnopharmacol. 2019 Feb 11. pii: S0378-8741(18)31263-7. doi: 10.1016/j.jep.2019.02.021. [Epub ahead of print] PubMed PMID: 30763693.
|
| Additional Infomation |
Neoandrographolide is a diterpenoid glycoside. It has been reported to be found in Andrographis paniculata, Lemna minor, and Caladium arborescens, and relevant data are available for reference.
Neoandrographolide is a primary bioactive constituent of Andrographis paniculata. Its distinct glucoside structure provides it with pharmacological properties different from andrographolide, particularly in terms of oral bioavailability. It is a promising candidate for anti-inflammatory and cardioprotective drug development. |
| Molecular Formula |
C26H40O8
|
|---|---|
| Molecular Weight |
480.5910
|
| Exact Mass |
480.272
|
| CAS # |
27215-14-1
|
| PubChem CID |
9848024
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
668.1±55.0 °C at 760 mmHg
|
| Melting Point |
167-168ºC
|
| Flash Point |
220.1±25.0 °C
|
| Vapour Pressure |
0.0±4.6 mmHg at 25°C
|
| Index of Refraction |
1.576
|
| LogP |
2.11
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
811
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@]1(CCC[C@@]2([C@@H]1CCC(=C)[C@H]2CCC3=CCOC3=O)C)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
YGCYRQKJYWQXHG-RDNQFMDVSA-N
|
| InChi Code |
InChI=1S/C26H40O8/c1-15-5-8-19-25(2,14-33-24-22(30)21(29)20(28)18(13-27)34-24)10-4-11-26(19,3)17(15)7-6-16-9-12-32-23(16)31/h9,17-22,24,27-30H,1,4-8,10-14H2,2-3H3/t17-,18-,19-,20-,21+,22-,24-,25+,26+/m1/s1
|
| Chemical Name |
4-[2-[(1R,4aS,5R,8aS)-5,8a-dimethyl-2-methylidene-5-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethyl]-2H-furan-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~208.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 25 mg/mL (52.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 250.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0808 mL | 10.4039 mL | 20.8078 mL | |
| 5 mM | 0.4162 mL | 2.0808 mL | 4.1616 mL | |
| 10 mM | 0.2081 mL | 1.0404 mL | 2.0808 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
